

# C62

## Liquid Chromatography-Mass Spectrometry Methods

This document provides guidance to the clinical laboratorian for the reduction of interlaboratory variance and the evaluation of interferences, assay performance, and other pertinent characteristics of clinical assays. This guideline emphasizes particular areas related to assay development and presents a standardized approach for method verification that is specific to mass spectrometry technology.

A guideline for global application developed through the Clinical and Laboratory Standards Institute consensus process.

# Clinical and Laboratory Standards Institute

*Setting the standard for quality in medical laboratory testing around the world.*

The Clinical and Laboratory Standards Institute (CLSI) is a not-for-profit membership organization that brings together the varied perspectives and expertise of the worldwide laboratory community for the advancement of a common cause: to foster excellence in laboratory medicine by developing and implementing medical laboratory standards and guidelines that help laboratories fulfill their responsibilities with efficiency, effectiveness, and global applicability.

## Consensus Process

Consensus—the substantial agreement by materially affected, competent, and interested parties—is core to the development of all CLSI documents. It does not always connote unanimous agreement but does mean that the participants in the development of a consensus document have considered and resolved all relevant objections and accept the resulting agreement.

## Commenting on Documents

CLSI documents undergo periodic evaluation and modification to keep pace with advances in technologies, procedures, methods, and protocols affecting the laboratory or health care.

CLSI's consensus process depends on experts who volunteer to serve as contributing authors and/or as participants in the reviewing and commenting process. At the end of each comment period, the committee that developed the document is obligated to review all comments, respond in writing to all substantive comments, and revise the draft document as appropriate.

Comments on published CLSI documents are equally essential and may be submitted by anyone, at any time, on any document. All comments are managed according to the consensus process by a committee of experts.

## Appeal Process

When it is believed that an objection has not been adequately considered and responded to, the process for appeal, documented in the CLSI *Standards Development Policies and Processes*, is followed.

All comments and responses submitted on draft and published documents are retained on file at CLSI and are available upon request.

## Get Involved—Volunteer!

Do you use CLSI documents in your workplace? Do you see room for improvement? Would you like to get involved in the revision process? Or maybe you see a need to develop a new document for an emerging technology? CLSI wants to hear from you. We are always looking for volunteers. By donating your time and talents to improve the standards that affect your own work, you will play an active role in improving public health across the globe.

For additional information on committee participation or to submit comments, contact CLSI.

Clinical and Laboratory Standards Institute

P: +1.610.688.0100

F: +1.610.688.0700

[www.clsi.org](http://www.clsi.org)

[standard@clsi.org](mailto:standard@clsi.org)

---

## Liquid Chromatography-Mass Spectrometry Methods

William Clarke, PhD, MBA, DABCC  
Ross J. Molinaro, PhD, MLS(ASCP)<sup>CM</sup>, DABCC, FACB  
Lorin M. Bachmann, PhD, DABCC, MT(ASCP)  
Julianne Cook Botelho, PhD  
Zhimin Cao, MD, PhD, DABCC  
Deborah French, PhD, DABCC  
Seema Garg, MS, MBA  
John M. Gawoski, MD  
Russell P. Grant, PhD

Andrew N. Hoofnagle, MD, PhD  
Bagyalakshmi Iyer, PhD  
Vathany Kulasingam, PhD, FCACB  
Donald S. Mason, MS  
Brian Rappold  
Danyel H. Tacker, PhD, DABCC  
Steven M. Truscott, PhD, DABCC  
Chunli Yu, MD, FACMG  
Yusheng Zhu, PhD, DABCC, FACB

### Abstract

---

Clinical and Laboratory Standards Institute guideline C62—*Liquid Chromatography-Mass Spectrometry Methods* provides guidance for the development and verification of liquid chromatography-mass spectrometry (LC-MS) methods in the clinical laboratory. The document is intended to reduce interlaboratory variance for clinical assays through guidance for evaluating interferences, assay performance, and other pertinent characteristics. It emphasizes particular areas related to assay development and presents a standardized approach for method verification that is specific to mass spectrometry (MS) technology. This document is intended for laboratorians responsible for development and verification of MS-based assays, physicians who may use these assays for patient care decisions, external quality assessment programs, and manufacturers of MS instrumentation and reagent kits designed to be paired with a particular mass spectrometer. This document is limited to discussion of LC-MS and is focused on the steps for development of a method, eg, whether the analyte is a drug, hormone, protein, or peptide.

Clinical and Laboratory Standards Institute (CLSI). *Liquid Chromatography-Mass Spectrometry Methods*. 2nd ed. CLSI guideline C62 (ISBN 978-1-68440-154-3 [Print]; ISBN 978-1-68440-155-0 [Electronic]). Clinical and Laboratory Standards Institute, USA, 2022.

The Clinical and Laboratory Standards Institute consensus process, which is the mechanism for moving a document through two or more levels of review by the health care community, is an ongoing process. Users should expect revised editions of any given document. Because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, users should replace outdated editions with the current editions of CLSI documents. Current editions are listed in the CLSI catalog and posted on our website at [www.clsi.org](http://www.clsi.org).

**If you or your organization is not a member and would like to become one, or to request a copy of the catalog, contact us at:**

**P:** +1.610.688.0100 **F:** +1.610.688.0700 **E:** [customerservice@cls.org](mailto:customerservice@cls.org) **W:** [www.clsi.org](http://www.clsi.org)

Copyright ©2022 Clinical and Laboratory Standards Institute. Except as stated below, any reproduction of content from a CLSI copyrighted standard, guideline, companion product, or other material requires express written consent from CLSI. All rights reserved. Interested parties may send permission requests to [permissions@clsi.org](mailto:permissions@clsi.org).

CLSI hereby grants permission to each individual member or purchaser to make a single reproduction of this publication for use in its laboratory procedure manual at a single site. To request permission to use this publication in any other manner, e-mail [permissions@clsi.org](mailto:permissions@clsi.org).

## Suggested Citation

CLSI. *Liquid Chromatography-Mass Spectrometry Methods*. 2nd ed. CLSI guideline C62. Clinical and Laboratory Standards Institute; 2022.

**Previous Edition:**

October 2014

C62-Ed2

ISBN 978-1-68440-154-3 (Print)

ISBN 978-1-68440-155-0 (Electronic)

ISSN 1558-6502 (Print)

ISSN 2162-2914 (Electronic)

Volume 42, Number 16

.....

## Committee Membership

### Consensus Council

The Consensus Council sets priorities for CLSI standards development and votes on Final Draft documents to confirm that process requirements have been met. Consensus Council members are listed on the CLSI website: <https://clsi.org/standards-development/consensus-council/>

### Document Development Committee on Liquid Chromatography/Mass Spectrometry Methods

**William Clarke, PhD, MBA, DABCC**  
**Chairholder**  
**Johns Hopkins Medical Institutions**  
**USA**

Julianne Cook Botelho, PhD  
 Centers for Disease Control and  
 Prevention  
 USA

Andrew N. Hoofnagle, MD, PhD  
 University of Washington  
 Medical Center  
 USA

**Ross J. Molinaro, PhD, MLS(ASCP)<sup>CM</sup>,  
 DABCC, FACB**  
**Vice-Chairholder**  
**Siemens Healthcare Diagnostics, Inc.**  
**USA**

Zhimin Cao, MD, PhD, DABCC  
 New York State Department of Health  
 USA

Vathany Kulasingam, PhD, FCACB  
 University Health Network  
 Canada

Lorin M. Bachmann, PhD, DABCC,  
 MT(ASCP)  
 Virginia Commonwealth University  
 USA

Russell P. Grant, PhD  
 LabCorp  
 USA

Donald S. Mason, MS  
 Waters Corporation  
 USA

### Expert Panel on Chemistry and Toxicology

Expert Panel volunteers support the development of CLSI documents by providing technical expertise in specialty areas. Expert Panel members are listed by area of expertise on the CLSI website: <https://clsi.org/standards-development/expert-panels/>

### Staff

Clinical and Laboratory Standards  
 Institute  
 USA

Laura Martin  
*Editorial Manager*

Kristy L. Leirer, MS  
*Editor*

Emily J. Gomez, MS,  
 MLS(ASCP)<sup>CM</sup>MB<sup>CM</sup>  
*Project Manager*

Catherine E.M. Jenkins, ELS  
*Editor*

Lisa M.W. Walker, MS, ELS  
*Editor*

## Acknowledgment

---

CLSI, the Consensus Council, the Expert Panel on Clinical Chemistry and Toxicology, the Consensus Committee on Clinical Chemistry and Toxicology, and the Document Development Committee on Liquid Chromatography/Mass Spectrometry Methods gratefully acknowledge the following volunteers for their important contributions to the development of this guideline in 2014 and its limited revision in 2022:

Lorin M. Bachmann, PhD, DABCC,  
MT(ASCP)  
Virginia Commonwealth University  
Health System  
USA

William Clarke, PhD, MBA, DABCC  
Johns Hopkins Medical Institutions  
USA

Deborah French, PhD, DABCC  
University of California San Francisco  
USA

Seema Garg, MS, MBA  
Eurofins Medinet  
USA

John M. Gawoski, MD  
Lahey Hospital & Medical Center  
USA

Bagyalakshmi Iyer, PhD  
Pennsylvania Department of Health  
USA

Brian Rappold  
Essential Testing, LLC  
USA

Danyel H. Tacker, PhD, DABCC  
West Virginia University Hospitals  
USA

Steven M. Truscott, PhD, DABCC  
Beaumont Health System  
USA

Chunli Yu, MD, FACMG  
Mount Sinai Genetic Testing  
Laboratory  
USA

Yusheng Zhu, PhD, DABCC, FACB  
Medical University Hospital Authority  
USA

# Contents

Abstract	i
Committee Membership	iii
Foreword	vii
Chapter 1: Scope	1
Chapter 2: Standard Precautions	3
Chapter 3: Terminology	5
3.1 A Note on Terminology	6
3.2 Definitions	7
3.3 Abbreviations and Acronyms	10
Chapter 4: Instrumentation	13
4.1 High-Performance Liquid Chromatography and Ultra-High Performance Liquid Chromatography	14
4.2 Ion Sources for Mass Spectrometry	16
4.3 Mass Analyzers: Quadrupole, Time-of-Flight, and Ion Traps	17
4.4 Instrumentation Performance Parameters	19
Chapter 5: Preexamination Considerations	25
5.1 Analyte of Interest	26
5.2 Internal Standard Selection	28
5.3 Reagents and Sample Preparation	30
Chapter 6: Assay Development	33
6.1 Ion Transitions	34
6.2 High-Performance Liquid Chromatography Stationary Phase	37
6.3 High-Performance Liquid Chromatography Mobile Phase	37
6.4 Examination Variables	39
6.5 Sources of Error	47
6.6 Assay Calibration	50
6.7 Preverification	55
Chapter 7: Assay Verification	61
7.1 Limit of Detection and Lower Limit of the Measuring Interval	62
7.2 Linearity and Dilution	62
7.3 Imprecision	64
7.4 Assay Interferences	65
7.5 Trueness	66

## Contents (Continued)

<b>Chapter 8: Quality Assurance and Quality Control of Liquid Chromatography-Mass Spectrometry Assays</b> .....	<b>69</b>
8.1 Selection of Quality Control Materials .....	70
8.2 Quality Control Concentration and Frequency .....	71
8.3 Additional Quality Assurance/Quality Control Samples for Liquid Chromatography-Mass Spectrometry Methods .....	72
8.4 Evaluation of Quality Control Acceptability .....	73
8.5 Corrective Action for Failed Quality Control.....	73
8.6 Quality Control Considerations for Multicomponent or Multiplexed Assays.....	73
8.7 Periodic Quality Assurance Procedures.....	74
8.8 Additional Quality Assurance Aspects .....	76
<b>Chapter 9: Postimplementation Monitoring</b> .....	<b>77</b>
9.1 Proficiency Testing.....	78
9.2 System Performance Monitoring .....	79
<b>Chapter 10: Supplemental Information</b> .....	<b>83</b>
<b>References</b> .....	84
<b>The Quality Management System Approach</b> .....	92

## Foreword

---

The importance of mass spectrometry (MS) in the clinical laboratory is increasing, and this CLSI document was developed in response to the need for increased robustness and harmonization of liquid chromatography-mass spectrometry (LC-MS) methods. Vendors of *in vitro* diagnostic devices often wait until the clinical utility of a particular assay is established and widely accepted before beginning development of a commercial assay. As a result, improvements in patient care can be delayed until a commercial assay is available. These delays can be significant if there are difficulties in the development of the assay. For laboratories with the capability to develop and implement laboratory-developed tests, MS provides an attractive alternative solution based on the ability to rapidly develop an analytically robust assay with excellent analytical sensitivity and specificity. In some cases, it offers an attractive alternative to commercially available assays that have already been developed, but do not offer acceptable performance in the current clinical context. LC-MS technology shows promise as a tool to rapidly develop clinical assays for emerging biomarkers coming from research in proteomics. Advances in instrumentation are likely to enable application of LC-MS technology in routine clinical diagnostic testing.

Despite the significant advantages that can be gained from incorporating MS into the clinical laboratory, considerable challenges exist. Among these is the fact that for some assays, significant laboratory-to-laboratory variability for the same analyte has been observed. There is currently limited assay standardization for MS-based methods, and much of the assay variability can be attributed to the lack of commercially available calibrators; that is, each clinical laboratory must formulate its own calibrators. For example, some sites may use powdered or commercially lyophilized material, some may use organic solvent solutions, and some may even use formulations obtained from their institution's pharmacy to make calibrators. Moreover, the preparation of the calibrators also varies from using solutions made in buffer, from using analyte-free serum or plasma as the matrix, or from using patient specimen remnants as the calibrator matrix—a problem for endogenous analytes. Differences in chromatographic methods from site to site lead to variable matrix effects during analysis. In addition, many laboratories verify their assays using various protocols in accordance with different regulatory or industry standards. This document addresses these issues by providing guidance for the development and verification of LC-MS methods in the clinical laboratory.

This document outlines many important elements for successful implementation of LC-MS technology for clinical analyses. The basic instrument components needed both for chromatography and MS are discussed, along with instrument parameters that must be optimized for development of robust LC-MS methods. In addition, the document contains a discussion of preexamination considerations that must be addressed during the method development process. Various elements of method development are summarized, along with best practice recommendations for addressing those elements during the process. Guidance is provided for verification of an LC-MS method, including a recommendation for preverification evaluation before full method verification. Finally, the document provides guidance for QA, including assay QC and postimplementation monitoring.

## Overview of Changes

This guideline was revised in 2022 under the Limited Revision Process and replaces the first edition of the guideline, which was published in 2014. The sole change made in this edition is distinguishing recommended criteria for intralaboratory evaluation from studies required for regulatory submissions.

### KEY WORDS

**Chromatography**

**Mass spectrometry**

**Postimplementation monitoring**

**Liquid chromatography-mass spectrometry**

**Method verification**

**Quality control**

# Chapter 1

## Scope

# Liquid Chromatography-Mass Spectrometry Methods

## 1 Scope

This document provides an introduction to, and guidance for, method development, verification, and postimplementation monitoring of quantitative clinical applications using liquid chromatography-mass spectrometry (LC-MS). While LC-MS may also be used for qualitative analyses, the focus of this document is on the use of this technology for quantification of clinical analytes. In addition, while there are commercial and research methods that allow direct injection without chromatography for rapid analyses, this guideline is exclusively focused on liquid chromatography (LC) coupled to mass spectrometry (MS). The purpose of this guideline is to educate both clinical LC-MS practitioners and health care providers (including physicians) who may use these assays for patient care decisions on the benefits and limitations of LC-MS methods used in the clinical laboratory, as well as provide a practical guide for the development and implementation of LC-MS–based clinical applications. It is intended to serve not only as a companion to CLSI document C50,<sup>1</sup> which serves as excellent general guidance for MS in the clinical laboratory, but also to provide an enhanced focus on methods, best practices, and instrumentation related to LC-MS, which is emerging as the most common approach to clinical analyses. This document is also intended to be a resource for instrument manufacturers, manufacturers of LC-MS reagents, regulatory agencies, and educators, as well as individuals responsible for developing laboratory standards and policy.

A description of all current clinical applications of LC-MS, as well as all of the pertinent information regarding development and verification of these methods, is beyond the scope of this document. As such, this guideline directs the reader to appropriate existing resources wherever possible. In providing guidance for LC-MS method development, verification, and implementation, this document focuses on:

- Important features of LC-MS instrumentation
- Preexamination factors that can impact assay performance and utility
- Assay calibration
- Analytical variables important in method development
- Assay verification
- QA and QC
- Postimplementation monitoring of clinical methods